Related Experiment Videos
Immunoglobulin therapy in the West syndrome
1Department of Pediatrics, Koshigaya Hospital, Dokkyo University School of Medicine, Saitama, Japan.
Brain & Development
|January 1, 1987
Summary
High-dose non-treated immunoglobulin (NTIG) therapy shows promise for early West syndrome (WS) treatment. NTIG achieved complete remission in cryptogenic WS and improved seizures in symptomatic WS, suggesting a neuroprotective effect.
Area of Science:
- Neurology
- Immunology
- Pediatrics
Background:
- West syndrome (WS) is a severe form of epilepsy in infants.
- Early intervention is crucial to prevent cognitive decline and developmental impairment.
- Current treatments for WS have limitations and variable efficacy.
Purpose of the Study:
- To evaluate the efficacy of high-dose non-treated immunoglobulin (NTIG) therapy in early-stage West syndrome.
- To assess the impact of NTIG on seizure control and electroencephalogram (EEG) normalization.
- To investigate the potential of NTIG in preventing brain deterioration associated with epileptic encephalopathy.
Main Methods:
- Administered high-dose NTIG (100-200 mg/kg) intravenously 6-10 times over 2-3 week intervals.
- Included patients with cryptogenic WS (n=6) and symptomatic WS (n=5).
- Monitored seizure activity, EEG patterns, and neurological status post-treatment.
Main Results:
- Complete remission with normalized EEG was observed in all cryptogenic WS patients, without anticonvulsants.
- One symptomatic WS patient achieved seizure cessation and EEG improvement.
- Two symptomatic WS patients experienced transient seizure cessation with recurrence.
- Power spectrum analysis showed decreased delta and increased theta wave activity post-NTIG therapy in responders.
Conclusions:
- High-dose NTIG therapy is a potentially effective early treatment for cryptogenic West syndrome.
- NTIG may help inhibit brain deterioration in infants with West syndrome.
- Further research is warranted to optimize NTIG protocols for symptomatic WS.